http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Myriad Genetics (MYGN) and Illumina (ILMN) Expand Partnership for HRD Testing in the US
-
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
-
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
-
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
-
Illumina To Webcast Upcoming Investor Conference
-
John Hancock expands access to GalleriĀ®, GRAIL's breakthrough cancer screening technology
-
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute
-
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
-
Illumina (ILMN) Appoints Joydeep Goswami as CFO
-
Illumina Appoints Joydeep Goswami Chief Financial Officer
-
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
-
Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina Ranks Among Top Scores on Dow Jones Sustainability Index and CDP
-
Illumina To Webcast Upcoming Investor Conferences
-
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022
-
ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS
-
Twist Bioscience Corporation (TWST) and Illumina (ILMN) Partner to Produce Robust Exome Panel to Advance Research
-
Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research
-
Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States
-
Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
-
Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022
-
Illumina (ILMN) Enters Strategic Research Collaboration with AstraZeneca (AZN) to Accelerate Drug Target Discovery
-
Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery
-
Illumina to Announce Third Quarter 2022 Financial Results on Thursday, November 3, 2022
-
Illumina (ILMN) Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum
-
Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum
-
Illumina (ILMN) Announces Launch of NovaSeq X Series
-
Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health
-
Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream
-
John Hancock becomes the first life insurance carrier to offer access to GRAIL's multi-cancer early detection test to customers
-
Illumina to Host Upcoming Investor Day
-
Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care
-
Illumina (ILMN) Announces New Round of Startup Investments
-
Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications
-
Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure
-
llumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call
-
Illumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders
-
Illumina (ILMN) Intends to Appeal European Commission's Decision in GRAIL Deal
-
Illumina Intends to Appeal European Commission's Decision in GRAIL Deal
-
Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal
-
Illumina Deepens Commitment to Customers in China with New Manufacturing Site
-
Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight
-
Illumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki
-
Minderoo Foundation and Illumina Commit $40M AUD to Apply Advanced Genomics to Marine Conservation
-
Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics
-
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022
-
Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
-
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
-
Illumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama

